Laura Alder, Thoracic Medical Oncologist at Duke Cancer, shared on X:
“Great work from Jessie (Stuart) Ross, Charlie Rudin and team! Tarlatamab in DLL3-high pulmonary carcinoid: 73% ORR, 100% DCR! n=11. Tox notable: CRS 82%, 22% gr3. DLL3 is a real target beyond SCLC! Higher CRS: tumor biology, or the uniformly high DLL3 expression?”
Title: Clinical Responses to Tarlatamab Among Patients with Pulmonary Carcinoid
Authors: Jessica S. Ross, Jake Lee, Eduardo Ortiz, Onur Yildirim, Rania G. Aly, Prithviraj Solanki, Natasha Rekhtman, Charles M. Rudin.
Read the full article.
This also can be interesting:
EGFR Amplification in EGFR-Mutated NSCLC: Critical Risk Marker
